You have 9 free searches left this month | for more free features.

iNHL

Showing 1 - 25 of 51

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

Recruiting
  • Indolent Lymphoma
  • Low-dose Radiotherapy
  • Low-dose radiotherapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 13, 2022

Cough Trial in Hamilton (Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml)

Completed
  • Cough
  • Salbutamol 5mg/mL
  • Sodium Chloride 0.9% Inhl 3Ml
  • Hamilton, Ontario, Canada
  • +1 more
Jun 13, 2022

Obinutuzumab in Chinese Real-world Patients With iNHL

Not yet recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • Changzhou, Jiangsu, China
  • +24 more
Jul 23, 2023

Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))

Completed
  • Lymphoma, Non-Hodgkin
  • Copanlisib (Aliqopa, BAY80-6946)
  • Beijing, China
    Beijing Cancer Hospital
May 17, 2021

Non Hodgkin Lymphoma Trial in Australia, United States (Tenalisib,)

Completed
  • Non Hodgkin Lymphoma
  • Huntsville, Alabama
  • +11 more
Jul 20, 2021

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)

Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Borddeaux Cedex, France
  • +9 more
Nov 11, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)

Terminated
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  • Rituximab
  • ALT-803
  • Minneapolis, Minnesota
  • +3 more
Feb 11, 2021

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)

Recruiting
  • Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
  • TAK-007
  • Chemotherapy Agents
  • Birmingham, Alabama
  • +18 more
Aug 17, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • +7 more
  • Chandler, Arizona
  • +199 more
Jan 31, 2023

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in Worldwide (pembrolizumab, Favezelimab)

Recruiting
  • Hodgkin Disease
  • +2 more
  • pembrolizumab
  • Favezelimab
  • Gilbert, Arizona
  • +24 more
Aug 18, 2022

Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib, Rituximab, Bendamustine)

Recruiting
  • Follicular Lymphoma (FL)
  • +2 more
  • Tucson, Arizona
  • +134 more
Jul 27, 2022

Asthma, Cough Trial in Hamilton (Mannitol, Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml)

Completed
  • Asthma
  • Cough
  • Mannitol
  • +2 more
  • Hamilton, Ontario, Canada
    McMaster University
Feb 12, 2020

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
Apr 21, 2022

Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))

Active, not recruiting
  • Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
  • Blinatumomab Expanded T-cells (BET)
  • Bergamo, Italy
    ASST - Papa Giovanni XXIII
Dec 22, 2021

Advanced Solid Tumor and Lymphoma Malignancies Trial in Worldwide (TAK-659)

Completed
  • Advanced Solid Tumor and Lymphoma Malignancies
  • Sarasota, Florida
  • +14 more
Jul 15, 2021

Indolent Non-hodgkin Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Washington, District of Columbia
  • +39 more
May 17, 2021

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,

Withdrawn
  • Indolent Non-Hodgkin's Lymphoma
  • +3 more
  • Plainville, Connecticut
  • +6 more
Mar 15, 2021

Hematologic Cancer Trial in Israel, United States (ABBV-101)

Not yet recruiting
  • Hematologic Cancer
  • Lone Tree, Colorado
  • +7 more
Feb 22, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (TAK-981, Rituximab)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Birmingham, Alabama
  • +58 more
Dec 7, 2022